|
Q2 FY2021
As of May 31, 2021
|
Q1 FY2021
As of Feb 28, 2021
|
Q4 FY2020
As of Nov 30, 2020
|
Q3 FY2020
As of Aug 31, 2020
|
Q2 FY2020
As of May 31, 2020
|
Q1 FY2020
As of Feb 29, 2020
|
Q4 FY2019
As of Nov 30, 2019
|
Q3 FY2019
As of Aug 31, 2019
|
Q2 FY2019
As of May 31, 2019
|
Q1 FY2019
As of Feb 28, 2019
|
Q4 FY2018
As of Nov 30, 2018
|
Q3 FY2018
As of Aug 31, 2018
|
Q2 FY2018
As of May 31, 2018
|
Q1 FY2018
As of Feb 28, 2018
|
Q4 FY2017
As of Nov 30, 2017
|
Q3 FY2017
As of Aug 31, 2017
|
Q2 FY2017
As of May 31, 2017
|
Q1 FY2017
As of Feb 28, 2017
|
Q4 FY2016
As of Nov 30, 2016
|
Q3 FY2016
As of Aug 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES AND STOCKHOLDERS' DEFICIENCY | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Loans from shareholder | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Stockholders' deficiency | ||||||||||||||||||||
| Common stock: $0.01 par value; 50,000,000 shares authorized; issued and outstanding: 11,200,000 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Deficit accumulated | ||||||||||||||||||||
| Total stockholders' deficiency | ||||||||||||||||||||
Loading...
